Applying Pharmacogenomic Guidelines to Combat Medical Care
Abstract
Pharmacogenomics is a pillar of personalized medicine that has the potential to deliver optimized treatment in many medical settings. Military medicine in the deployed setting is unique and therefore warrants separate assessment pertaining to its potential capabilities and impact. Pharmacogenomics for United States Active Duty Service Members medical care in the deployed setting has not, to our knowledge, been previously reviewed. We present potential applications of pharmacogenomics to forward medical care through two comprehensive references for deployed medical care, the Tactical Combat Casualty Care Guidelines (TCCC) and Emergency War Surgery (EWS) fifth edition. All drugs within the deployment manuals, TCCC guidelines and EWS book, were identified and the list was cross-referenced to the Clinical Pharmacogenetics Implementation Consortium guidelines and genes–drugs interactions list as well as the Food and Drug Administration Table of Pharmacogenomics Biomarkers in Drug Labeling. Ten pharmacologic categories were identified, consisting of 15 drugs, along with the classes, aminogylcosides, beta-blockers, and volatile anesthetics. Drugs and pharmacogenomics liabilities were tabulated. Eight specific drugs or classes are expounded upon given the belief of the authors of their potential for impacting future treatment on the battlefield in the setting of prolonged field care. This review outlines several genes with liabilities in the prolonged field care setting and areas that may produce improved care with further study.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 30, 2021
- Source ID
- 10.1093/milmed/usab333
Entities
People
- Chad Hulsopple
- Clesson E Turner
- Daniel J Selig
- Elaine Por
- Jeffrey Livezey
- Jesse Deluca
- Lydia D Hellwig
- Thomas Oliver
Organizations
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Uniformed Services University of the Health Sciences